These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38137700)

  • 1. Sevelamer Use and Mortality in People with Chronic Kidney Disease Stages 4 and 5 Not on Dialysis.
    Molina P; Molina MD; Carrero JJ; Escudero V; Torralba J; Castro-Alonso C; Beltrán S; Vizcaíno B; González-Moya M; Kanter J; Sancho-Calabuig A; Bover J; Górriz JL
    J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137700
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
    Habbous S; Przech S; Martin J; Garg AX; Sarma S
    Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis.
    Spoendlin J; Paik JM; Tsacogianis T; Kim SC; Schneeweiss S; Desai RJ
    JAMA Intern Med; 2019 Jun; 179(6):741-749. PubMed ID: 31058913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.
    Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.
    Palmer SC; Gardner S; Tonelli M; Mavridis D; Johnson DW; Craig JC; French R; Ruospo M; Strippoli GF
    Am J Kidney Dis; 2016 Nov; 68(5):691-702. PubMed ID: 27461851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.
    St Peter WL; Liu J; Weinhandl E; Fan Q
    Am J Kidney Dis; 2008 Mar; 51(3):445-54. PubMed ID: 18295060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
    Rastogi A
    Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D.
    Yusuf AA; Weinhandl ED; St Peter WL
    Am J Kidney Dis; 2014 Jul; 64(1):95-103. PubMed ID: 24387795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality in kidney disease patients treated with phosphate binders: a randomized study.
    Di Iorio B; Bellasi A; Russo D;
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):487-93. PubMed ID: 22241819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.
    Tonelli M; Wiebe N; Culleton B; Lee H; Klarenbach S; Shrive F; Manns B;
    Nephrol Dial Transplant; 2007 Oct; 22(10):2856-66. PubMed ID: 17906326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
    Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Calcium-based Phosphate Binders Versus Sevelamer on Mortality of Patients with Hemodialysis: A Meta-analysis.
    Zhang P; Sang S; Huang J; Feng S; Feng C; Wang R
    Iran J Kidney Dis; 2022 Jul; 16(4):215-227. PubMed ID: 35962636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study.
    Ruggeri M; Cipriani F; Bellasi A; Russo D; Di Iorio B
    Blood Purif; 2014; 37(4):316-24. PubMed ID: 25171148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia.
    Petrou P
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):287-298. PubMed ID: 30664365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
    Sekercioglu N; Thabane L; Díaz Martínez JP; Nesrallah G; Longo CJ; Busse JW; Akhtar-Danesh N; Agarwal A; Al-Khalifah R; Iorio A; Guyatt GH
    PLoS One; 2016; 11(6):e0156891. PubMed ID: 27276077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
    Bernard L; Mendelssohn D; Dunn E; Hutchison C; Grima DT
    J Med Econ; 2013; 16(1):1-9. PubMed ID: 22857538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.